AMPE - Ampio Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.6900
+0.0020 (+0.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.6880
Open0.7003
Bid0.6782 x 1100
Ask0.6900 x 800
Day's Range0.6700 - 0.7200
52 Week Range0.2600 - 0.9100
Volume1,701,530
Avg. Volume2,620,950
Market Cap113.747M
Beta (5Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)-0.1330
Earnings DateAug 06, 2020 - Aug 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%
    Zacks

    Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%

    Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • Ampio to Start First Clinical Trial in COVID-19 Program
    PR Newswire

    Ampio to Start First Clinical Trial in COVID-19 Program

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company"), is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").

  • Ampio Provides Update on COVID-19 Program
    PR Newswire

    Ampio Provides Update on COVID-19 Program

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").

  • What You Must Know About Ampio Pharmaceuticals, Inc.'s (NYSEMKT:AMPE) Beta Value
    Simply Wall St.

    What You Must Know About Ampio Pharmaceuticals, Inc.'s (NYSEMKT:AMPE) Beta Value

    If you're interested in Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE), then you might want to consider its beta (a...

  • Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampionâ„¢ for COVID-19 Patients
    PR Newswire

    Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampionâ„¢ for COVID-19 Patients

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development of immunology based therapies for prevalent inflammatory conditions, today announced a manuscript accepted for publication in The Journal of Patient Safety in Surgery that showed Ampion treatment could improve clinical outcomes for COVID-19 patients.

  • Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampionâ„¢ to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)
    PR Newswire

    Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampionâ„¢ to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today that it was featured on a FOX segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug," reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 ("COVID-19") infection is Acute Respiratory Distress Syndrome ("ARDS"), and there are no approved treatments for ARDS or COVID-19. The segment featured the Company's application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion.

  • Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial
    PR Newswire

    Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the "Company"), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clinical trial of Ampion ("AP-013") for the treatment of severe osteoarthritis of the knee ("OAK"). The trial focuses on individuals with the most severely diseased OAK, which represents an underserved patient population typically excluded from clinical studies because of the intractable nature of their condition. The average and maximum age of a patient in the AP-013 clinical trial is 65 and 87 years old, respectively. The Centers for Disease Control and Prevention ("CDC") have indicated that older adults, 65 years and older, are at higher risk for severe illness during the current COVID-19 pandemic.

  • Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19
    PR Newswire

    Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions for which limited treatment options exist, announced today that it is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 ("COVID-19") induced Acute Respiratory Distress Syndrome ("ARDS"), an immediately life-threatening condition.

  • Ampio Provides Corporate Update
    PR Newswire

    Ampio Provides Corporate Update

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment ("SPA") Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampionâ„¢ to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and receipt of its annual audit opinion.

  • Here is What Hedge Funds Think About Ampio Pharmaceuticals, Inc. (AMPE)
    Insider Monkey

    Here is What Hedge Funds Think About Ampio Pharmaceuticals, Inc. (AMPE)

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number
    PR Newswire

    Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampionâ„¢ to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and its manufacturing facility.

  • Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility
    PR Newswire

    Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility

    ENGLEWOOD, Colo., Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of AmpionTM to treat Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced updates of the continued progress with their Phase III AP-013 clinical trial and their "state-of-the-Art" manufacturing facility. "It is important to note," Ms. Cherevka continued, "in the three randomized single-injection studies previously run by the Company, both reduction in pain and improvement in function were significantly greater for KL 4 patients treated with Ampion vs saline.

  • Ampio Retains Legal Counsel for Transaction Advisory Committee
    PR Newswire

    Ampio Retains Legal Counsel for Transaction Advisory Committee

    ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled  "Evaluating the Efficacy and Safety of Ampion to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced that Cooley LLP has been engaged to represent Ampio with respect to a potential strategic transaction, as well as related matters.

  • Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial
    PR Newswire

    Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

    ENGLEWOOD, Colo. , Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE)   today announced the progress to date in the Company's special protocol assessment (SPA) phase three ...

  • Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee
    PR Newswire

    Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee

    ENGLEWOOD, Colo., Aug. 22, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a special protocol assessment (SPA) phase three clinical trial titled, "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion™ in Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced that the Company has retained Torreya Partners LLC as a financial advisor and has appointed Willam Bindley and Bruce E. Terker to a newly formed Transaction Advisory Committee (TAC).